Uzansertib

N/A

Report date: 2026/02/25 20:02:36

NME

Base Information

Drug NameUzansertib

Drug Alias NameINCB-053914INCB-53914

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsSerine/threonine-protein kinase pim-2 inhibitorsSerine/threonine-protein kinase pim-3 inhibitors

TargetsProto-oncogene serine/threonine-protein kinase Pim-1Serine/threonine-protein kinase pim-2Serine/threonine-protein kinase pim-3

Therapy Area/IndicationsSolid tumoursMyelodysplastic-Myeloproliferative DiseasesLymphoma, Large B-Cell, Diffuse

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesIncyte Corp

China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp

Inactive CompaniesN/A

Active IndicationsMyelodysplastic-Myeloproliferative Diseases

Inactive IndicationsSolid tumoursLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A